Cont B2

3. (Amended) The parvovirus vector according to claim 1 or 2, [characterized in that] wherein the parvovirus minimal origin of replication comprises [the] a consensus sequence of an NS1 nicking site[, particularly CTWWTCA].

4. (Amended) The parvovirus vector according to [any one of claims 1 to 3, characterized in that] claim 1 or 2, wherein the parvovirus DNA originates from a mammalian parvovirus.

5. (Amended) The parvovirus vector according to [any one of claims 1 to 3, characterized in that] claim 1 or 2, wherein the parvovirus DNA is a rodent parvovirus.

6. (Amended) The parvovirus vector according to claim 5, [characterized in that] wherein the rodent parvovirus is MVM or H-1.

7. (Amended) The parvovirus vector according to [any one of claims 1 to 3, characterized in that] claim 1 or 2, wherein the parvovirus DNA comprises a combination of DNA sequences of various parvoviruses.

8. (Amended) The parvovirus vector according to claim 7, [characterized in that] wherein the parvovirus DNA originates from H-1 and [its] the left terminus comprises a minimal parvovirus origin of replication of MVM.

9. (Amended) The parvovirus vector according to [any one of claims 1 to 8, characterized in that] claim 1 or 2, wherein the parvovirus DNA region coding for [the] capsid proteins is partially or fully replaced by an exogeneous DNA.

10. (Amended) The parvovirus vector according to claim 9, [characterized in that] wherein the exogeneous DNA codes for a polypeptide usable in a treatment.

11. (Amended) The parvovirus vector according to claim 10, [characterized in that] wherein the polypeptide is a [cytokin] cytokine or a toxin.

12. (Amended) The parvovirus vector according to claim 11, [characterized in that] wherein the [cytokin] cytokine is a chemotactic polypeptide.

13. (Amended) The parvovirus vector according to claim 12, [characterized in that] wherein the chemotactic polypeptide is MCP-1.

14. (Amended) The parvovirus vector according to [any one of claims 1 to 13, characterized in that it] claim 1 or 2, wherein the parvovirus vector is present as a parvoviral particle.

15. (Amended) A system comprising the parvovirus vector according to [any one of claims 9 to 13] claim 9 and a cell expressing the capsid proteins of parvovirus.

16. (Amended) The system according to ~~claim~~ 15, [characterized in that] wherein the expression of the capsid proteins is controlled by a helper plasmid [containing] comprising an SV40 origin of replication and the cell expresses an SV40 large T antigen.

17. (Amended) The system according to claim 15, [characterized in that] wherein the DNA coding for the capsid proteins is under the control of the parvovirus promoter P38.

18. (Amended) A method of producing the parvoviral particle according to claim 14, comprising the [transfection of] steps of:
transfecting a parvovirus-permissive cell with [a] the parvovirus vector according to [any one of claims 9 to 13] claim 9,
expressing [the cell expressing] the capsid proteins of a parvovirus in the cell, and
isolating [the isolation of] the parvoviral particle.

19. (Amended) Use of the parvovirus vector according to [any one of claims 9 to 14] claim 9 for gene therapy.

20. (Amended) Use according to claim 19, [characterized in that] wherein the gene therapy is carried out in the case of tumor diseases.

Add new claim 21.

-- 21. (New) The parvovirus vector according to claim 3, wherein said consensus sequence of an NS1 nicking site is CTWWTCA. --

TGAXXAG